<DOC>
	<DOCNO>NCT00144807</DOCNO>
	<brief_summary>This study multicentric trial evaluate efficacy R-ACVBP patient age 18 59 year high risk diffuse large B-cell lymphoma</brief_summary>
	<brief_title>ACVBP Plus Rituximab Patients Aged From 18 59 Years With High-risk Diffuse Large B-cell Lymphoma</brief_title>
	<detailed_description>This phase II non randomize study base result LNH 98-5 , LNH 87-2 , LNH 93-3 LNH 98-3B study . To date , ACVBP regimen consider reference induction treatment GELA patient 2-3 adverse prognostic factor . Indeed neither NCVBP regimen ( LNH87-2 ) ECVBP ( LNH93-3 ) lead increase complete remission rate . More recently , addition etoposide doxorubicin cyclophosphamide ( LNH98-3B ) enhance complete remission rate toxicity . In patient &lt; 60 year 2-3 adverse prognostic factor complete remission rate remain less 65 % study . Consequently , increase quality response remain major goal group young patient adverse prognostic factor . It show addition rituximab CHOP regimen significantly improve CR rate elderly patient previously untreated large B-cell lymphoma compare CHOP alone without additional toxicity . Moreover , event-free survival overall survival find long R-CHOP group . The present trial evaluate response rate obtain four cycle ACVBP combine rituximab ( R-ACVBP ) high dose therapy consolidative treatment group high risk patient . The LNH87-2 study show intensive consolidation treatment autologous stem cell support beneficial high risk patient good response full induction phase . The long-term result randomise study prompt u consider high dose therapy best consolidative option patient .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Patient histologically proven CD20+ diffuse large Bcell lymphoma ( WHO classification ) . Age 18 59 year , eligible transplant . Patient previously treat . Age adjust IPI = 2 3 With minimum life expectancy 3 month Negative HIV , HBV HCV serologies &lt; 4 week ( except vaccination ) . Having sign write informed consent . Any history treat nontreated indolent lymphoma . However , patient previously diagnose diffuse large Bcell lymphoma small cell infiltration bone marrow lymph node may include . Central nervous system meningeal involvement lymphoma . Contraindication drug contain chemotherapy regimen . Poor renal function ( creatinin level &gt; 150 mmol/l ) , poor hepatic function ( total bilirubin level &gt; 30 mmol/l , transaminases &gt; 2.5 maximum normal level ) unless abnormality relate lymphoma . Poor bone marrow reserve define neutrophil &lt; 1.5 G/l platelet &lt; 100 G/l , unless relate bone marrow infiltration . Any history cancer last 5 year exception nonmelanoma skin tumor stage 0 ( situ ) cervical carcinoma . Any serious active disease ( accord investigator 's decision ) . Treatment investigational drug within 30 day plan first cycle chemotherapy study . Pregnant lactate woman Adult patient tutelage .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>lymphoma , diffuse large B-cell</keyword>
	<keyword>rituximab</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>autologous stem cell transplant</keyword>
</DOC>